NuGene International has announced that its subsidiary corporation, NuGene BioPharma, has acquired all rights, title and interest in and to SkinGuardian, an FDA-approved (monographed) skin protectant, antiseptic, and moisturizing topical cream.

NuGene BioPharma acquired all intellectual property held by SkinGuardian and its founder and owner, Chris O’Brien, relating to the SkinGuardian technology and applications. This includes the patent under which the technology is protected, the company trademark, all formulas and derivatives under the patent, clinical trial data, and any and all other rights, title and interest in and to the SkinGuardian product. Under the agreement, O’Brien will provide ongoing consultation to NuGene International, Inc.

“As stated previously, NuGene’s stem cell technologies and applications extend beyond the cosmeceutical and hair care market, the focus of NuGene International,” explained NuGene International’s CEO Ali Kharazmi when announcing the acquisition. “We decided to form NuGene BioPharma in order to develop and market FDA-approved products that have pharmacological properties that can enhance the healing of wounds and skin conditions.”